Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Total Equity history
Currency unavailable · from the balance sheet
No Total Equity data reported for this period type.
Total Equity vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $471.51M USD | +65.0% | +191.8% | 94.8% |
| Mar 2026 | $399.83M USD | +330.0% | +180.0% | 95.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $378.69M USD | +3546.2% | — | 96.2% |
| Mar 2026 | $280.77M USD | -45.1% | -14.7% | 64.8% | |
| Mar 2026 | $263.38M USD | -15.1% | +3.8% | 95.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $250.04M USD | +35.3% | +88.0% | 95.7% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $70.68M USD | -69.0% | — | 45.9% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +35.3% | +88.0% | 95.5% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.